U.S. Physical Therapy (NYSE:USPH) Stock Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of U.S. Physical Therapy, Inc. (NYSE:USPH). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in U.S. Physical Therapy stock on April 17th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of RTX (NYSE:RTX) on 4/23/2025.
• Purchased $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 4/22/2025.
• Purchased $1,001 – $15,000 in shares of Techtronic Industries (OTCMKTS:TTNDY) on 4/21/2025.
• Purchased $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 4/21/2025.
• Purchased $1,001 – $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of KKR & Co. Inc. (NYSE:KKR) on 4/21/2025.
• Purchased $1,001 – $15,000 in shares of D.R. Horton (NYSE:DHI) on 4/21/2025.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Hillman Solutions (NASDAQ:HLMN) on 4/17/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 4/17/2025.

U.S. Physical Therapy Stock Performance

Shares of NYSE USPH opened at $79.90 on Friday. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $71.85 and its two-hundred day moving average is $83.54. The company has a market cap of $1.21 billion, a P/E ratio of 84.99, a P/E/G ratio of 3.54 and a beta of 1.44. U.S. Physical Therapy, Inc. has a 12 month low of $62.77 and a 12 month high of $107.09.

U.S. Physical Therapy (NYSE:USPH) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.02. The business had revenue of $183.79 million for the quarter, compared to analysts’ expectations of $176.78 million. U.S. Physical Therapy had a return on equity of 8.11% and a net margin of 3.54%. U.S. Physical Therapy’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.51 earnings per share. On average, equities analysts expect that U.S. Physical Therapy, Inc. will post 2.67 EPS for the current year.

U.S. Physical Therapy Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 23rd will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 2.25%. The ex-dividend date is Friday, May 23rd. U.S. Physical Therapy’s dividend payout ratio is currently 82.57%.

Insider Buying and Selling at U.S. Physical Therapy

In other U.S. Physical Therapy news, COO Graham D. Reeve sold 1,730 shares of U.S. Physical Therapy stock in a transaction on Friday, March 7th. The stock was sold at an average price of $82.11, for a total value of $142,050.30. Following the completion of the transaction, the chief operating officer now owns 7,168 shares in the company, valued at approximately $588,564.48. The trade was a 19.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of U.S. Physical Therapy

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in U.S. Physical Therapy by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,084,197 shares of the company’s stock valued at $96,179,000 after buying an additional 6,393 shares in the last quarter. Copeland Capital Management LLC boosted its stake in U.S. Physical Therapy by 9.5% in the 4th quarter. Copeland Capital Management LLC now owns 839,356 shares of the company’s stock valued at $74,459,000 after buying an additional 72,715 shares in the last quarter. Southernsun Asset Management LLC boosted its stake in U.S. Physical Therapy by 4.5% in the 4th quarter. Southernsun Asset Management LLC now owns 571,809 shares of the company’s stock valued at $50,725,000 after buying an additional 24,698 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in U.S. Physical Therapy by 1.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 426,298 shares of the company’s stock valued at $37,818,000 after buying an additional 7,890 shares in the last quarter. Finally, Bahl & Gaynor Inc. raised its position in U.S. Physical Therapy by 32.6% in the 1st quarter. Bahl & Gaynor Inc. now owns 345,003 shares of the company’s stock valued at $24,964,000 after purchasing an additional 84,878 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on USPH shares. Barrington Research lowered their price objective on U.S. Physical Therapy from $108.00 to $98.00 and set an “outperform” rating on the stock in a research report on Friday, February 28th. William Blair restated a “market perform” rating on shares of U.S. Physical Therapy in a research report on Thursday, February 27th. JPMorgan Chase & Co. lowered their price objective on U.S. Physical Therapy from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 19th. StockNews.com upgraded U.S. Physical Therapy from a “sell” rating to a “hold” rating in a research report on Thursday, May 8th. Finally, JMP Securities restated a “market outperform” rating and set a $113.00 price objective on shares of U.S. Physical Therapy in a research report on Tuesday, April 22nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.00.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.